Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.

Abstract

In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either naftidrofuryl (600 mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p less than 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symptoms and lengthens the painfree walking distance in patients with arterial occlusive disease.

• Authors: G Trübestein, H Böhme, H Heidrich, F Heinrich, H Hirche, U Maass, H Mörl, G Rudofsky
• Journal: Angiology (Angiology) Vol. 35 Issue 11 Pg. 701-8 (Nov 1984) ISSN: 0003-3197 [Print] United States
• PMID: 6388425 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Furans
• Placebos
• Nafronyl

Topics

• Adult
• Arterial Occlusive Diseases (drug therapy)
• Blood Flow Velocity
• Blood Pressure
• Chronic Disease
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Furans (therapeutic use)
• Humans
• Male
• Middle Aged
• Nafronyl (therapeutic use)
• Placebos
• Statistics as Topic